HRD Negative / Low in Prostate Cancer
• HRD (Homologous Recombination Deficiency) status reflects defects in DNA repair pathways.
• HRD-positive prostate cancers (e.g., with BRCA1/2 mutations) may respond well to PARP inhibitors.
• A negative/low HRD status means the tumor is less likely to benefit from PARP inhibitor therapy.
• Standard hormonal therapy, chemotherapy, or novel agents may be better options.
